<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03538314</url>
  </required_header>
  <id_info>
    <org_study_id>UV1/hTERT-MM-103</org_study_id>
    <nct_id>NCT03538314</nct_id>
  </id_info>
  <brief_title>UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma</brief_title>
  <official_title>A Phase I, Open-label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-line Malignant Melanoma Patients Planned for Treatment With Pembrolizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultimovacs ASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ultimovacs ASA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      UV1 is a therapeutic cancer vaccine that has been explored in prostate and lung cancers, and&#xD;
      in combination with ipilimumab in malignant melanoma. This study will explore the safety,&#xD;
      tolerability and efficacy of UV1 administered with GM-CSF in melanoma patients who are also&#xD;
      receiving pembrolizumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>UV1/GM-CSF</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment-related adverse events</measure>
    <time_frame>Up to week 29</time_frame>
    <description>Frequency and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Up to week 52</time_frame>
    <description>RECIST and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The length of time from the start of treatment that patients are still alive.</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Experimental Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UV1/GM-CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UV1</intervention_name>
    <description>UV1 (300 microgram)</description>
    <arm_group_label>Experimental Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>GM-CSF (37,5 or 75 microgram)</description>
    <arm_group_label>Experimental Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Stage IIIB, IIIC or IV melanoma&#xD;
&#xD;
          2. Previously untreated and eligible for pembrolizumab treatment (prior treatment with&#xD;
             BRAF and MEK inhibitors permitted) 3) Adequate blood, liver and kidney function 4)&#xD;
             Consent to undergo tumor biopsies during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uveal or ocular malignant melanoma&#xD;
&#xD;
          2. History of hematologic or primary solid tumor malignancy with the exception of&#xD;
             patients in remission for at least 5 years, as judged by the investigator are allowed&#xD;
&#xD;
          3. Prior systemic treatment for unresectable or metastatic melanoma. Exception: Prior&#xD;
             treatment with BRAF and MEK inhibitors permitted. A washout period of at least&#xD;
             3-half-lives (median terminal half-life) prior to the first dose of trial treatment&#xD;
             must have elapsed.&#xD;
&#xD;
          4. Prior therapy with an anti-CTLA4, anti-PD-1, anti-PD-L1, anti-PD-L2 agent or oncolytic&#xD;
             virus.&#xD;
&#xD;
          5. Known hypersensitivity to GM-CSF&#xD;
&#xD;
          6. Women who are breastfeeding, pregnant or expect to be pregnant during the study&#xD;
             through 6 months after the last dose&#xD;
&#xD;
          7. Men who plan to become a father during the study through 4 months after the last dose&#xD;
             of study medication&#xD;
&#xD;
          8. Known history of, or any evidence of active, non-infectious pneumonitis&#xD;
&#xD;
          9. History of cardiac disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>John Wayne Cancer Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Carver College of Medicine</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 22, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2018</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

